But axions were pushed aside as the WIMPs hypothesis gained more steam. Back-of-the-envelope calculations showed that the ...

BMS' radiopharma unit builds with $1.35bn Philochem deal. Bristol Myers Squibb has expanded its push into radiopharma by licensing a prostate cancer therapy developed by Philochem for $350m upfront.

Novartis has struck another deal to strengthen its position in radiopharmaceuticals, agreeing to pay $1 billion upfront for radioligand therapy (RLT) developer Mariana Oncology.

Objects made of iron have a reassuring solidness, but that’s not the reason it’s called the most stable element.